Puma Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Puma Biotechnology has a total shareholder equity of $71.1M and total debt of $78.1M, which brings its debt-to-equity ratio to 109.8%. Its total assets and total liabilities are $220.7M and $149.6M respectively. Puma Biotechnology's EBIT is $33.0M making its interest coverage ratio 3.7. It has cash and short-term investments of $96.7M.
Key information
109.8%
Debt to equity ratio
US$78.08m
Debt
| Interest coverage ratio | 3.7x |
| Cash | US$96.73m |
| Equity | US$71.09m |
| Total liabilities | US$149.63m |
| Total assets | US$220.72m |
Recent financial health updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Recent updates
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Financial Position Analysis
Short Term Liabilities: PBYI's short term assets ($156.8M) exceed its short term liabilities ($110.4M).
Long Term Liabilities: PBYI's short term assets ($156.8M) exceed its long term liabilities ($39.2M).
Debt to Equity History and Analysis
Debt Level: PBYI has more cash than its total debt.
Reducing Debt: PBYI's debt to equity ratio has reduced from 548.2% to 109.8% over the past 5 years.
Debt Coverage: PBYI's debt is well covered by operating cash flow (43.2%).
Interest Coverage: PBYI's interest payments on its debt are well covered by EBIT (3.7x coverage).